Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Eye Toward Stroke Prevention:Central Retinal Artery Occlusion and Tandem Internal Carotid Artery Occlusion
Stroke 55:e165-e168, Cheronis,C.,et al, 2024
Diagnosis and Management of Cerebral Venous Thrombosis: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Stroke 42:1158-1192, Saposnik,G.,et al, 2011
Stroke
Lancet 371:1612-1623, Donnan,G.A.,et al, 2008
Treatment of Childhood Arterial Ischemic Stroke
Ann Neurol 63:679-696, Bernard,T.J.,et al, 2008
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Prospective Study of Endogenous Tissue Plasminogen Activator and Risk of Stroke
Lancet 343:940-943, Ridker,P.M.,et al, 1994
Stroke Complic Acute MI, A Meta-Analysis of Risk Modific by Antigoac & Thrombolytic Therapy
Arch Int Med 152:2020-2024, Viatkus,P.T.,et al, 1992
Antithrombotic Therapy in Cerebrovascular Disease
Ann Int Med 115:885-895, Rothrock,J.F.&Hart,R.G., 1991
Current Medical & Surgical Therapy for Cerebrovascular Disease
NEJM 317:1505-1516, Grotta,J.C., 1987
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Vaccine-Induced Thrombocytopenia with Severe Headache
NEJM 385:doi:10.1056/NEJMc2112974, Salih, F.,et al, 2021
Increasing Prevalence of Vascular Risk Factors in Patients with Stroke
Neurol 89:1985-1994, Otite, F.O.,et al, 2017
Major Risk Factors for Aneurysmal Subarrachnoid Hemorrhage in the Young are Modifiable
Stroke 34:1375-1381, Broderick,J.P.,et al, 2003
Improved Cerebrovascular Patency Following Therapy in Patients with Sickle Cell Disease: Initial Results in 4 Patients Who Received HLA-Identical Hematopoietic Stem Cell Allografts
Ann Neurol 49:222-229, Steen,R.G.,et al, 2001